Alnylam

Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race
First Word Pharma
Tue, 11/26/24 - 11:04 am
Alnylam
FDA
RNAi
vutrisiran
ATTR-CM
Alnylam boots Type 2 diabetes asset from haunted house
Fierce Biotech
Fri, 11/1/24 - 11:09 am
Alnylam
RNAi
type 2 diabetes
Alnylam agrees to drop patent lawsuit against Moderna over Covid-19 vaccine
Reuters
Sun, 10/6/24 - 10:50 pm
Alnylam
Moderna Therapeutics
legal
patents
vaccines
Alnylam’s vutrisiran aces ATTR cardiomyopathy readout
Pharmaphorum
Mon, 06/24/24 - 10:52 am
Alnylam
RNAi
vutrisiran
ATTR
cardiomyopathy
Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace
Fierce Pharma
Mon, 04/22/24 - 06:01 pm
Alnylam
Pfizer
Amvuttra
ATTR-CM
tafamidis
Alnylam changes to heart drug trial spark doubts, sinking shares
BioPharma Dive
Thu, 02/15/24 - 07:13 pm
Alnylam
clinical trials
vutrisiran
ATTR
Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection
BioSpace
Thu, 10/26/23 - 10:39 am
Alnylam
Patisiran
clinical trials
FDA
ATTR with cardiomyopathy
Interest in RNA Editing Accelerates as Therapies Approach the Clinic
BioSpace
Wed, 10/18/23 - 11:37 am
RNA editing
Alnylam
Shape Therapeutics
Eli Lilly
ProQR Therapeutics
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Pharma Voice
Thu, 10/12/23 - 05:32 pm
Alnylam
Pharma CEOs
Yvonne Greenstreet
FDA
Onpattro
FDA denies expanded approval for Alnylam RNA drug
BioPharma Dive
Mon, 10/9/23 - 10:15 am
Alnylam
FDA
RNA
Patisiran
ATTR amyloidosis
With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam
Fierce Pharma
Mon, 10/2/23 - 06:36 pm
Novo Nordisk
Rivfloza
FDA
primary hyperoxaluria type 1
RNAi
Alnylam
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Fierce Pharma
Mon, 09/18/23 - 08:01 pm
Pfizer
BridgeBio
Alnylam
FDA
clinical trials
ATTR-CM
physicians
tafamidis
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Fierce Pharma
Thu, 09/14/23 - 09:59 am
Alnylam
FDA
Onpattro
ATTR-CM
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
BioSpace
Tue, 09/12/23 - 07:06 pm
Alnylam
FDA
ATTR-CM
Onpattro
Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
BioSpace
Thu, 09/7/23 - 10:49 pm
Alnylam
Roche
PAH
zilebesiran
clinical trials
Agios and Alnylam sign agreement for siRNA candidate
Pharmaceutical Business Review
Fri, 08/4/23 - 12:09 pm
Agios Pharmaceuticals
Alnylam
siRNA
polycythemia vera
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
BioSpace
Mon, 07/24/23 - 11:29 am
Roche
Alnylam
RNAi
hypertension
zilebesiran
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
Tue, 07/18/23 - 11:55 am
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug
Clinical Trials Arena
Mon, 07/17/23 - 08:41 am
Alnylam
clinical trials
ALN-APP
Alzheimer's disease

Pages